The following is a summary of “Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...